Keyphrases
Antiretroviral Therapy
48%
Europe
35%
Confidence Interval
29%
HIV-positive
29%
HIV Patients
26%
CD4 Count
26%
People Living with HIV (PLHIV)
23%
EuroSIDA
21%
Combined Antiretroviral Therapy (cART)
20%
AIDS/HIV
19%
HIV Infection
19%
Donor-acceptor
19%
Viral Load
16%
D Study
16%
COVID-19
14%
Risk Factors
12%
Cardiovascular Disease
11%
Cardiovascular Risk
10%
Virological Failure
9%
Randomized Trial
9%
Eastern Europe
9%
Non-AIDS Comorbidities
9%
Antiretroviral
9%
Antiviral Drugs
9%
Human Immunodeficiency Virus Type 1 (HIV-1)
9%
Protease Inhibitors
8%
Myocardial Infarction
8%
Incidence Rate
7%
Highly Active Antiretroviral Therapy (HAART)
7%
Adverse Events
7%
Tuberculosis
7%
HIV RNA
7%
AIDS-defining Illness
7%
Human Immunodeficiency Virus Infection
6%
Hepatitis C Virus
6%
Comorbidity
6%
Clinical Outcomes
6%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
6%
Cytomegalovirus
6%
Chronic Kidney Disease
6%
Interleukin-6
6%
Hospitalized Patients
6%
HIV Testing
5%
Viral Suppression
5%
Co-infected Patients
5%
Antiretroviral Therapy Regimens
5%
Strategic Timing
5%
Abacavir
5%
Non-AIDS Events
5%
Odds Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Infection
19%
Disease
19%
Cardiovascular Disease
17%
Human Immunodeficiency Virus Infection
16%
Proteinase Inhibitor
10%
Malignant Neoplasm
10%
Cohort Study
10%
Adverse Event
9%
Biological Marker
7%
Prevalence
7%
Hepatitis C Virus
7%
Clinical Trial
7%
Anti-Human Immunodeficiency Virus
7%
Heart Infarction
7%
Drug Resistance
6%
Nonnucleoside Reverse Transcriptase Inhibitor
6%
Chronic Kidney Failure
5%
Placebo
5%
Hepatitis C
5%
Inflammation
5%
Medicine and Dentistry
Human Immunodeficiency Virus
79%
Antiretroviral Therapy
33%
Infection
18%
Disease
11%
Cell Count
10%
Cardiovascular Disease
10%
Human Immunodeficiency Virus Infection
10%
Cohort Analysis
8%
Transplantation
8%
COVID-19
7%
Prevalence
7%
Proteinase Inhibitor
6%
Drug Resistance
6%
Odds Ratio
5%
Malignant Neoplasm
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Biological Marker
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Adverse Event
5%
